Desferrioxamine, deferiprone and deferasirox for the treatment of chronic iron overload in people with thalassaemia
Status Suspended
Decision Selected
Process MTA
Referral date 01 July 2010
Topic area
  • Blood and immune system
  • Endocrine, nutritional and metabolic

Scoped within Batch 12

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: Shalu Kanal
Executive Lead: Peter Littlejohns
Project manager: Jeremy Powell
Technical Lead: Raisa Sidhu


Manufacturers/sponsors Apotex (deferiprone)
  Swedish Orphan Biovitrum (deferiprone)
  Hospira (desferrioxamine)
  Novartis Pharmaceuticals (deferasirox, desferrioxamine)
Others Department of Health
  NHS Eastern and Coastal Kent Teaching
  NHS Northamptonshire
  Welsh Assembly Government
Patient/carer groups Action for Children
  Action for Sick Children
  Afiya Trust
  Black Health Agency
  Children’s Society
  Chinese National Healthy Living Centre
  Counsel and Care
  Equalities National Council
  Genetic Alliance UK
  Muslim Council of Britain
  Muslim Health Network
  National Children’s Bureau
  National Parent Partnership Network
  Sickle Cell Society
  South Asian Health Foundation
  Specialised Healthcare Alliance
  United Kingdom Thalassaemia Society
Professional groups British Association for Services to the Elderly
  British Committee for Standards in Haematology
  British Geriatric Society
  British Society for Haematology
  British Society for Human Genetics
  NHS Sickle Cell & Thalassaemia Screening Programme
  National Pharmacy Association
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Paediatrics & Child Health
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  UK Forum on Haemoglobin Disorders
  United Kingdom Clinical Pharmacy Association
  United Kingdom National Screening Committee
Assessment Group Liverpool Reviews & Implementation Group, University of Liverpool
  National Institute for Health Research Health Technology Assessment Programme
Associated Guideline Groups National Clinical Guidelines Centre
Associated Public Health Groups None
Comparator manufacturer(s) None
General Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Commissioning Support Appraisals Service
  Department of Health,Social Services and Public Safety for Northern Ireland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  Public Health Wales NHS Trust
  NHS Alliance
  NHS Commercial Medicines Unit
  NHS Confederation
  NHS Quality Improvement Scotland
  Scottish Medicines Consortium
Relevant research groups MRC Clinical Trials Unit
  National Institute for Health Research
  Policy Research Institute on Ageing and Ethnicity
  Research Institute for the Care of Older People

For further information on our processes and methods, please see our CHTE processes and methods manual